Clinical assessment
Symptoms, physical findings, jaundice, weight loss, diabetes changes, family history and inherited-risk context help guide testing.
Pancreatic Cancer Education · Diagnosis · Imaging · TNM Staging
Pancreatic Cancer Diagnosis & Staging
Pancreatic cancer diagnosis and staging help identify whether a suspicious pancreatic finding is cancer, define the tumor type, evaluate spread, and guide treatment planning. Evaluation may include blood tests, pancreas-protocol CT, MRI/MRCP, endoscopic ultrasound, biopsy, ERCP, pathology and TNM staging.
Educational information only. This page does not provide diagnosis, screening
instructions, treatment recommendations, or medical advice.
CT
MRI/MRCP
EUS-FNA
CA19-9
TNM
Diagnosis Overview
How pancreatic cancer may be diagnosed
Pancreatic cancer evaluation often begins after symptoms such as jaundice, abdominal or back pain, unexplained weight loss, dark urine, pale stools, digestive changes, or new diabetes. Diagnosis usually combines clinical review, imaging, blood tests, and tissue confirmation when needed.
Imaging and blood tests
CT, MRI/MRCP, EUS, liver function tests, bilirubin and CA19-9 may help assess the pancreas, bile duct, vessels and possible spread.
Biopsy and staging
EUS-guided biopsy, ERCP sampling, laparoscopy or other tissue methods may confirm pathology and support staging decisions.
Diagnosis Pathway
Common steps in pancreatic cancer evaluation
The diagnostic pathway depends on symptoms, imaging findings, jaundice, surgical planning, whether spread is suspected, and whether tissue confirmation is needed before treatment.
1
Symptoms and medical history
Jaundice, dark urine, pale stools, itchy skin, abdominal pain, back pain, weight loss, appetite loss, pancreatitis, diabetes and family history may be reviewed.
2
Blood tests
Blood tests may include liver function tests, bilirubin, complete blood count, kidney function, glucose and CA19-9 interpreted in context.
3
CT scan / pancreas protocol CT
CT can evaluate tumor location, size, nearby blood vessels, lymph nodes, liver, peritoneum and distant organs.
4
MRI and MRCP
MRI/MRCP may clarify pancreatic, liver, bile duct or pancreatic duct findings, especially when CT is inconclusive or more duct detail is needed.
5
Endoscopic ultrasound and biopsy
EUS can create detailed images from inside the digestive tract and may guide fine-needle aspiration or biopsy for tissue confirmation.
6
ERCP or staging laparoscopy
ERCP may sample abnormal areas or place a stent for bile duct blockage. Staging laparoscopy may look for small-volume spread not visible on imaging.
Diagnostic Map
Symptoms
CT
MRI
EUS
Biopsy
Diagnostic Tests
Tests used in pancreatic cancer diagnosis
No single test explains every case. Doctors may combine imaging, blood tests, endoscopic procedures, tissue sampling and pathology to understand the diagnosis.
Blood chemistry and bilirubin
Helps assess bile-flow blockage, liver involvement, jaundice, kidney function, inflammation and general treatment-readiness factors.
CA19-9 blood test
CA19-9 may support monitoring and evaluation, but it cannot diagnose pancreatic cancer alone and can be elevated in non-cancer bile duct conditions.
CT scan
A major imaging test for pancreatic cancer, often used to assess tumor size, spread, vessels and surgical possibility.
MRI / MRCP
MRI provides soft-tissue detail. MRCP gives detailed views of bile ducts and pancreatic ducts.
Endoscopic ultrasound
EUS can provide close-up pancreas images and may guide fine-needle biopsy or aspiration.
Biopsy / cytology
Tissue or cell sampling may confirm cancer type, especially before chemotherapy, radiation, targeted therapy or clinical trial treatment.
ERCP
ERCP can examine bile and pancreatic ducts, sample abnormal tissue, and place a bile duct stent when needed.
Staging laparoscopy
A minimally invasive procedure that may detect small peritoneal or liver surface spread not seen on scans.
CA19-9
Marker
Not alone
Bile duct context
Follow-up
CA19-9 Clarity
What CA19-9 can and cannot tell you
CA19-9 is a pancreatic cancer-associated marker, but it is not a stand-alone diagnostic test. It may be affected by bile duct blockage, inflammation, liver disease and other non-cancer conditions.
Useful in context
CA19-9 is interpreted with symptoms, imaging, bilirubin level, pathology and treatment history.
Not specific
A high CA19-9 does not automatically mean pancreatic cancer, and a normal CA19-9 does not always exclude it.
Monitoring role
In confirmed pancreatic cancer, CA19-9 may help follow treatment response or recurrence risk when appropriate.
TNM & Clinical Groups
How pancreatic cancer staging works
Pancreatic cancer is commonly staged using the TNM system, which describes tumor size and extension, lymph-node involvement and distant metastasis. Clinicians may also describe the cancer by whether surgery may be possible.
T
Tumor extent
Describes tumor size and whether the tumor involves nearby structures or major blood vessels.
N
Lymph nodes
Describes whether pancreatic cancer has spread to nearby regional lymph nodes.
M
Distant metastasis
Describes whether cancer has spread to distant organs or sites, such as the liver, peritoneum or lungs.
TNM Stage
I
II
III
IV
TNM
Surgical Planning Groups
Resectable, borderline, locally advanced and metastatic
In pancreatic cancer, staging is often connected with whether the tumor can be removed safely by surgery. This depends strongly on imaging of nearby arteries, veins and metastatic spread.
Resectable
Tumor appears removable by surgery with no distant metastasis and acceptable relationship to major blood vessels.
Borderline resectable
Tumor has limited vessel involvement or other features that may require treatment before surgery is considered.
Locally advanced
Tumor involves nearby structures or vessels in a way that usually prevents immediate safe removal, but distant spread may not be present.
Metastatic
Cancer has spread to distant organs or sites, such as liver, peritoneum, lungs or distant lymph nodes.
Stage Groups
Pancreatic cancer stages I to IV
Stage grouping summarizes the extent of disease. Exact staging depends on tumor size, vessel involvement, lymph nodes, metastasis, imaging and pathology.
Stage I
Cancer is limited to the pancreas and is usually smaller, without lymph-node spread or distant metastasis.
Stage II
Cancer may be larger or may involve nearby lymph nodes, but distant metastasis is not present.
Stage III
Cancer may involve major nearby blood vessels and/or more extensive regional lymph-node disease, without distant metastasis.
Stage IV
Cancer has spread to distant organs or sites, such as the liver, peritoneum, lungs or distant lymph nodes.
Pathology
What pathology can show
Pathology helps confirm cancer type, grade and tissue features. Molecular testing may be discussed for inherited-risk genes, DNA repair genes and therapy-related biomarkers.
Type
Tumor type
Examples include pancreatic ductal adenocarcinoma, acinar carcinoma and pancreatic neuroendocrine tumor.
Grade
Tumor grade
Grade describes how abnormal tumor cells look and may relate to tumor behavior.
Margins
Surgical margins
After surgery, pathology may describe whether cancer cells are close to or present at a removed tissue edge.
Genes
Molecular testing
Testing may include KRAS, BRCA1/2, PALB2, mismatch repair genes, NTRK or other markers depending on context.
Pathology Report
Type
Grade
Margins
Nodes
Molecular
Simple Summary
Pancreatic cancer diagnosis and staging in simple terms
Diagnosis identifies whether a suspicious pancreatic finding is cancer. Staging explains where the cancer is located, whether lymph nodes are involved and whether it has spread.
How is pancreatic cancer usually evaluated?
Evaluation may include symptom review, blood tests, CA19-9, CT scan, MRI/MRCP, endoscopic ultrasound, biopsy, ERCP and pathology.
What does TNM staging mean?
TNM describes the tumor, lymph nodes and metastasis. These findings are used to assign stage groups from I to IV.
Does CA19-9 diagnose pancreatic cancer?
No. CA19-9 can support evaluation and monitoring, but it cannot diagnose pancreatic cancer by itself.
FAQ
FAQ: Pancreatic Cancer Diagnosis & Staging
Clear answers to common diagnosis and staging search questions.
How is pancreatic cancer diagnosed?
Pancreatic cancer evaluation may include symptoms and history, blood tests, CA19-9, CT scan, MRI/MRCP, endoscopic ultrasound, biopsy, ERCP and pathology.
What is CA19-9 in pancreatic cancer?
CA19-9 is a blood marker associated with pancreatic cancer, but it can also be elevated in non-cancer bile duct or inflammatory conditions. It is interpreted with imaging and clinical context.
What imaging tests are used for pancreatic cancer?
CT scan, pancreas-protocol CT, MRI, MRCP, endoscopic ultrasound and sometimes PET or staging laparoscopy may be used depending on the case.
What are the stages of pancreatic cancer?
Pancreatic cancer is commonly grouped into stages I, II, III and IV. Stage IV means distant metastatic spread.
Is this page medical advice?
No. This page is educational only and does not replace consultation with a qualified healthcare professional.
References
Scientific References
Authoritative sources used to support this pancreatic cancer diagnosis and staging page.
- National Cancer Institute. Pancreatic cancer treatment PDQ and TNM staging information.
- American Cancer Society. Tests for pancreatic cancer and diagnostic imaging.
- Canadian Cancer Society. Diagnosis of pancreatic cancer and biopsy context.
- Cancer Research UK. Tests for pancreatic cancer, ERCP and CA19-9 information.
- ESMO Clinical Practice Guideline for pancreatic cancer diagnosis and staging.